Amgen's Kyprolis wins FDA myeloma nod; AZ sells thyroid drug to Sanofi's Genzyme;

> The FDA has approved Kyprolis for combo use in the treatment of patients with relapsed multiple myeloma. Release

> Bristol-Myers Squibb's ($BMY) hep C pill, Daklinza, has won FDA approval to be used in combination with Gilead's ($GILD) Sovaldi. Release

> AstraZeneca ($AZN) has inked a $300 million pact to sell thyroid carcinoma drug Caprelsa to Sanofi's ($SNY) Genzyme. Story

> After the close of Teva's ($TEVA) $40.5 billion deal for Allergan's generics business, the Israeli drugmaker will boast a commercial presence in 100 markets, including a top-three position in more than 40 of those markets, it said Monday. Release

And Finally... Television's Dr. Oz made $1.17 million off a hemorrhoid treatment he promoted in his column, Vox reports. More

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.